Pacira Biosciences Inc
NASDAQ:PCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pacira Biosciences Inc
NASDAQ:PCRX
|
US |
|
E
|
Eaton Corporation PLC
DUS:3EC
|
IE |
|
Cosel Co Ltd
TSE:6905
|
JP |
|
E
|
Eaton Corporation PLC
LSE:0Y3K
|
IE |
|
Voxtur Analytics Corp
XTSX:VXTR
|
CA |
|
Abbvie Inc
NYSE:ABBV
|
US |
|
Rush Enterprises Inc
NASDAQ:RUSHA
|
US |
|
Titan Machinery Inc
NASDAQ:TITN
|
US |
|
Sika AG
SIX:SIKA
|
CH |
|
NVIDIA Corp
NASDAQ:NVDA
|
US |
Wall St Price Targets
PCRX Price Targets Summary
Pacira Biosciences Inc
According to Wall Street analysts, the average 1-year price target for PCRX is 29.43 USD with a low forecast of 23.23 USD and a high forecast of 39.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PCRX's stock price target?
Price Target
29.43
USD
According to Wall Street analysts, the average 1-year price target for PCRX is 29.43 USD with a low forecast of 23.23 USD and a high forecast of 39.9 USD.
What is the Revenue forecast for Pacira Biosciences Inc?
Projected CAGR
0%
Over the last 13 years, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 8 years is 0%.
What is the Operating Income forecast for Pacira Biosciences Inc?
Projected CAGR
50%
The compound annual growth rate for Operating Income over the next 5 years is 50%.
What is the Net Income forecast for Pacira Biosciences Inc?
Projected CAGR
59%
The compound annual growth rate for Net Income over the next 7 years is 59%.
